AGNPF Stock Chart & Stats
$0.36
<$0.01(2.24%)
At close: 4:00 PM EDT
$0.36
<$0.01(2.24%)
Day’s Range― - ―
52-Week Range$0.22 - $0.67
Previous CloseN/A
Volume260.00
Average Volume (3M)4.13K
Market Cap
$2.87M
Enterprise Value$3.70
Total Cash (Recent Filing)$210.03K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume1,721
30 Day Avg. Volume4,131
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3.62
Revenue Forecast (FY)$33.03M
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetThe absence of debt reduces interest obligations and refinancing exposure, giving the company greater flexibility while it develops its digital health offerings. This is a durable financial advantage because a debt-free structure can preserve strategic options during continued commercialization and funding needs.
Narrowing Net LossesMeaningfully narrower losses indicate progress in controlling the company’s cost base, even though profitability remains negative. If this improvement continues, it could extend financial runway and reduce the scale of future funding requirements as the business works toward establishing revenue.
Improving Cash BurnThe reduction in free-cash-flow burn suggests improving cost discipline and a more manageable cash consumption profile. While the company is not yet self-funding, sustained improvement could slow capital needs and provide more time to achieve revenue scale or further reduce expenses.
Bears Say
No Revenue BaseZero reported revenue means the company has not yet demonstrated commercial traction or a repeatable monetization engine for its VR-based health applications. Until revenue begins to scale, future growth remains prospective and the business has limited evidence of operating self-sufficiency.
Persistent Cash BurnPersistent negative operating and free cash flow shows that the company cannot currently fund operations internally. Continued cash consumption may require external capital before revenue scale is reached, creating ongoing financing dependence and limiting flexibility to invest in growth.
Equity Erosion And Negative ReturnsPressured equity and consistently negative returns on equity reflect the cumulative impact of ongoing losses and indicate that invested capital is not yet producing positive economic returns. If losses persist, further value erosion could constrain the company’s ability to support long-term expansion.
Grey Matters Health News
AGNPF FAQ
What was Grey Matters Health’s price range in the past 12 months?
Grey Matters Health lowest stock price was $0.22 and its highest was $0.67 in the past 12 months.
What is Grey Matters Health’s market cap?
Grey Matters Health’s market cap is $2.87M.
When is Grey Matters Health’s upcoming earnings report date?
Grey Matters Health’s upcoming earnings report date is Dec 18, 2026 which is in 90 days.
How were Grey Matters Health’s earnings last quarter?
Grey Matters Health released its earnings results on Jul 29, 2026. The company reported -$0.093 earnings per share for the quarter.
Is Grey Matters Health overvalued?
According to Wall Street analysts Grey Matters Health’s price is currently Overvalued.
Does Grey Matters Health pay dividends?
Grey Matters Health does not currently pay dividends.
What is Grey Matters Health’s EPS estimate?
Grey Matters Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grey Matters Health have?
Grey Matters Health has 8,923,237 shares outstanding.
What happened to Grey Matters Health’s price movement after its last earnings report?
Grey Matters Health reported an EPS of -$0.093 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grey Matters Health?
Currently, no hedge funds are holding shares in AGNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Grey Matters Health
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―